https://www.matjournals.net/pharmacy/index.php/JPDRA/issue/feedJournal of Pharma and Drug Regulatory Affairs (e-ISSN:2582-3043)2026-08-07T08:51:06+00:00Open Journal Systems<p><strong>JPDRA</strong> provide platform to Researchers, Academicians, Scholars, and Professionals in the Pharmacy domain to promulgate their Research / Review / Case studies in the field of Drugs. The journal with a wide scope in the arena of pharmaceutical sciences covers the topics intended to be of interest to a broad audience of pharmaceutical professionals and ideally placed to serve the needs of their readers. The Scope of this Journal includes ICH/GCP, Regulatory Affairs for Medical Devices & Manufacturing Processes, Import and Export of Drugs, Biopharmaceutical Indian Regulations, Good Manufacturing Processes, Drug Mastery File and Dossier, Drug & Biologics Regulatory Affairs, DMF, Ayurvedic Regulations, Medical Diagnostics.</p>https://www.matjournals.net/pharmacy/index.php/JPDRA/article/view/400The Intellectual Property Landscape of Pharmaceutical Co-Crystals: Patent Strategies, Evergreening, and Ethical Debate2026-08-07T08:51:06+00:00Arvinder Kaurmanpreetrai045@gmail.comManpreet Singhmanpreetrai045@gmail.com<p><em>When pharmaceutical companies develop novel solid-state structures like co-crystals, the core active drug remains exactly the same. However, the medicine's shelf-life and how easily it dissolves can improve significantly. Multinational corporations frequently use these physical updates to secure secondary patents, which actively block cheaper generic medicines from reaching vulnerable patients. Global regulators handle this problem very differently. While the US and Europe still grant legal rights for simple structural changes, India relies on a strict law known as Section 3(d). Under this rule, a company must prove the new formulation actually improves therapeutic outcomes before winning a patent. Now, artificial intelligence is breaking these historical rules entirely. Because machine learning models can instantly predict these minor chemical shifts, the old legal defense that new drug shapes are "non-obvious" to invent is rapidly falling apart. To resolve this impending intellectual property crisis, this paper proposes a modernized three-part global framework. Regulators must adopt an efficacy-based patent standard worldwide, mandate strict transparency for AI use in laboratory research, and build faster legal pathways for generic drug challenges. Only by updating these rules can the system fairly reward true medical innovation while fiercely protecting global access to affordable care.</em></p>2026-08-07T00:00:00+00:00Copyright (c) 2026 Journal of Pharma and Drug Regulatory Affairs (e-ISSN:2582-3043)